Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:40:55.510Z.
Calculation as of: 2026-10-06T16:40:55.510Z.
Quote observation: 2026-10-06T16:40:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$288.79M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$287.54M
Price/FCF Ratio
N/A
TTM Avg
39.34
3Y Avg
39.34
5Y Avg
39.34
Market Cap
$287.63M
Price/FCF Ratio
N/A
TTM Avg
2.52
3Y Avg
2.52
5Y Avg
2.52
Market Cap
$282.70M
Price/FCF Ratio
N/A
TTM Avg
56.97
3Y Avg
56.97
5Y Avg
56.97
Market Cap
$295.55M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $288.79M | N/A | N/A | N/A | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.84M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $288.59M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $287.54M | N/A | 39.34 | 39.34 | 39.34 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | N/A | 2.52 | 2.52 | 2.52 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.70M | N/A | 56.97 | 56.97 | 56.97 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.55M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $281.53M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $303.00M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.29M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
